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Our objective was to determine the optimal approach for assessing
amyloid disease in a cognitively normal elderly population. Methods:
Dynamic 18F-flutemetamol PET scans were acquired using a coffee-
break protocol (a 0- to 30-min scan and a 90- to 110-min scan) on 190
cognitively normal elderly individuals (mean age, 70.4 y; 60% female).
Parametric images were generated from SUV ratio (SUVr) and non-
displaceable binding potential (BPND) methods, with cerebellar gray
matter as a reference region, and were visually assessed by 3 trained
readers. Interreader agreement was calculated using κ-statistics, and
semiquantitative values were obtained. Global cutoffs were calculated
for both SUVr and BPND using a receiver-operating-characteristic anal-
ysis and the Youden index. Visual assessment was related to semi-
quantitative classifications. Results: Interreader agreement in visual
assessment was moderate for SUVr (κ 5 0.57) and good for BPND
images (κ 5 0.77). There was discordance between readers for 35
cases (18%) using SUVr and for 15 cases (8%) using BPND, with 9
overlapping cases. For the total cohort, the mean (±SD) SUVr and
BPND were 1.33 (±0.21) and 0.16 (±0.12), respectively. Most of the
35 cases (91%) for which SUVr image assessment was discordant
between readers were classified as negative based on semiquantita-
tive measurements. Conclusion: The use of parametric BPND images
for visual assessment of 18F-flutemetamol in a population with low
amyloid burden improves interreader agreement. Implementing semi-
quantification in addition to visual assessment of SUVr images can
reduce false-positive classification in this population.
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Alzheimer disease (AD) is the most common cause of de-
mentia, accounting for 60%–80% of cases above 65 y of age (1).
Its pathologic hallmark is the accumulation of the amyloid-b
peptide, thought to start years before cognitive impairment (2).
In fact, abnormal amyloid-b levels are seen in 20%–40% of
cognitively normal subjects between the ages of 60 and 90 y
(3). These subjects are considered to be in the preclinical stage
of AD (4,5), which provides a unique opportunity for secondary
prevention studies and is gaining increasing research focus (6).
To this end, reliable identification of amyloid pathology in vivo
using PET is of the utmost importance in this population.
The identification of amyloid burden by means of visual inter-
pretation of summed late images or of semiquantitative SUV ratio
(SUVr) images is currently suggested to be sufficient. Previous
studies have shown a high interreader agreement for the visual
assessment of SUVr images and a high imaging–pathology corre-
lation in clinical populations and end-of-life subjects (7–9). It has
been shown, however, that SUVr overestimates amyloid burden
compared with quantitative nondisplaceable binding potential
(BPND) (10). As such, quantitative BPND images may be more
reliable also for visual interpretation. In a memory clinic popula-
tion, Zwan et al. showed that visual assessment of parametric
BPND 11C-Pittsburgh compound B images resulted in a higher
interreader agreement than the frequently used SUV and SUVr
images (11). To date, it remains to be determined whether these
findings translate to the increasingly available 18F-labeled amyloid-b
targeting tracers, such as 18F-flutemetamol, and, more importantly,
to the challenging population of cognitively normal elderly partic-
ipants who generally have a minimal amyloid load.
The purpose of this study was to compare 2 parametric imaging
methods (SUVr vs. BPND) to determine the optimal approach for
assessment of early amyloid pathology. To this end, we investigated
the agreement in visual assessment of SUVr and BPND images be-
tween 3 readers and its relationship to (semi-)quantitative measures.
MATERIALS AND METHODS
Project
The data used in this study originate from the Innovative Medicines
Initiative of the European Medical Information Framework for AD
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(http://www.emif.eu/). The overall aim of this project is to discover
and validate diagnostic markers, prognostic markers, and risk factors
for AD in nondemented subjects.
Subjects
In total, 199 subjects from the preclinical AD cohort were included
at the Vrije Universiteit (VU) Medical Center. Inclusion criteria were
an age of at least 60 y and normal cognition according to a delayed
recall score that was more than 21.5 SDs of the demographically
adjusted normative data on the Consortium to Establish a Registry
for Alzheimer Disease 10-word list (12), a Telephone Interview
for Cognitive Status–modified score of 23 or higher (13), a 15-item
Geriatric Depression Scale score of less than 11 (14), and a Clin-
ical Dementia Rating Scale score of 0 (15). Exclusion criteria were
any physical, neurologic, or psychiatric condition that interferes
with normal cognition. PET acquisition failed in 3 subjects, and 6
BPND images were lacking a visual assessment, resulting in 190
subjects who had a visual assessment for both SUVr and BPND
images. PET quantification failed in 5 subjects; thus, 185 subjects
were used for the quantitative analysis. Written informed consent
was obtained from all subjects, and the study was approved by the
Medical Ethics Review Committee of the VU University Medical
Center.
PET
PET scans were obtained using an Ingenuity TF PET/MRI camera
(Philips Healthcare). Thirty-minute scans were acquired immediately
after a manual injection of 18F-flutemetamol (191 6 20 MBq) (16).
After 60 min, during which the patient remained outside the scanner
bed, a second scan of 20 min was acquired, starting 90 min after
injection (17). Immediately before each part of the PET scan, a T1-
weighted gradient echo pulse MRI scan was acquired for attenuation
correction of the PET data. The first emission scan was reconstructed
into 18 frames of increasing length (6 · 5, 3 · 10, 4 · 60, 2 · 150, 2 ·
300, and 1 · 600 s) using the standard line-of-response–based row-
action maximum-likelihood algorithm for the brain. The second scan
was reconstructed with the same algorithm into 4 frames of 300 s each.
First, Vinci Software, version 2.56 (Max Planck Institute for Neurologic
Research), was used to combine the 2 PET scans into a single multi-
frame image. Next, each individual’s T1-weighted MR images were
coregistered to the dynamic PET images using the generic multimodal-
ity setting of Vinci with a linear rigid-body schema and normalized
mutual information as the similarity measure. Parametric BPND im-
ages were generated from the entire image set using the receptor
parametric mapping implementation in PPET (18–20). Generation
of the SUVr images was based on the 90- to 110-min scan interval.
Next, T1-based volumes of interest using the Hammers atlas imple-
mented in PVElab software were projected onto the PET images to
extract regional values (21). Cerebellar gray matter was used as
reference tissue for both analyses (22). Finally, we computed global
values based on the average of frontal (volume-weighted average
of superior, middle, and inferior frontal gyrus), parietal (volume-
weighted average of posterior cingulate, superior parietal gyrus,
postcentral gyrus, and inferolateral remainder of parietal lobe), and
temporal (volume-weighted average of parahippocampal gyrus; hip-
pocampus; medial temporal lobe; and superior, middle, and inferior
temporal gyrus) regions (23,24).
MRI
Whole-brain scans were obtained using the 3-T Achieva scanner
(Philips Healthcare) of the PET/MRI system described above equipped
with an 8-channel head coil. Isotropic structural 3-dimensional T1-
weighted images were acquired using a sagittal turbo field echo sequence
with the following settings: 1.00 · 1.00 · 1.00 mm voxels, repetition time
of 7.9 ms, echo time of 4.5 ms, and flip angle of 8. A 3-dimensional
sagittal fat-saturated fluid-attenuated inversion recovery sequence was
acquired using the following settings: 1.12 · 1.12 · 1.12 mm voxels,
repetition time of 4,800 ms, echo time of 279 ms, and inversion time
of 1,650 ms. The structural 3-dimensional T1 and 3-dimensional fluid-
attenuated inversion recovery images were used for assessment of global
cortical atrophy (25), average medial temporal atrophy (26), and Fazekas
score for white matter hyperintensities (27,28).
Visual Assessment of PET Images
Three trained readers, masked to clinical information, first assessed
all SUVr images and subsequently all BPND images, in a randomized
order. Images deemed dubious by the reader were reassessed on a
separate occasion. Images were scaled to 90% of the pons signal
using rainbow color scaling, and transverse, sagittal, and coronal
views were displayed using the software package Vinci, version 2.56.
Images were rated as either positive (binding in one or more corti-
cal brain regions or striatum unilaterally) or negative (predominantly
white matter uptake) according to criteria defined by the manufacturer
(GE Healthcare). PET images were assessed together with a T1-
weighted MR scan to limit the influence of atrophy on the visual
assessment.
The level of experience in visual assessment of 18F-flutemetamol
images differed among readers: a nuclear medicine physician with con-
siderable experience, a nuclear medicine physician trainee with basic
experience, and a radiologist in training with 6 mo of experience in
nuclear medicine. All readers completed the 18F-flutemetamol reader
training provided by GE Healthcare.
Statistical Analysis
Baseline demographics were assessed using simple descriptive sta-
tistical analyses. k-statistics were used to asses interreader agreement
among the 3 readers, intrareader agreement between the 2 methods, and
agreement between visual and semiquantitative classifications. Agree-
ment was considered poor if k was less than 0.20, satisfactory if k was
0.21–0.40, moderate if k was 0.41– 0.60, good if k was 0.61–0.80, and
excellent if k was more than 0.80. Differences in MRI measurements
between PET-negative and PET-positive cases were assessed using a
Mann–Whitney U analysis. The correlation between semiquantitative
SUVr and BPND measurements was assessed using Spearman r. Cutoffs
were calculated for both SUVr and BPND using a receiver-operating-
characteristic analysis and the Youden index. Possible overestimation of
amyloid burden using semiquantitative SUVr was investigated by cal-
culating the difference between SUVr 2 1 and BPND values. Differ-
ences in global overestimation between PET-negative and PET-positive
cases were assessed using a Mann–Whitney U analysis. Regional dif-
ferences in binding and overestimation were assessed using a Wilcoxon
paired test. Amyloid status resulting from quantitative assessment was
considered the true amyloid status for all analyses, in the absence of
postmortem confirmation.
RESULTS
Baseline demographics are provided in Table 1.
Visual Reads
Interreader agreement in visual assessment was moderate for
SUVr images (k 5 0.57) and good for BPND images (k 5 0.77).
There was discordance between readers for 35 cases (18%) using
SUVr and for 15 cases (8%) using BPND, with 9 overlapping cases.
Figure 1 shows examples of agreement and disagreement in visual
interpretation of 18F-flutemetamol images. On average, the rating
was positive in 35 (18%) of the SUVr images and in 26 (14%) of
the BPND images. The reader with the least experience classified
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55 (29%) SUVr images as positive, compared with 21 (11%) and
29 (15%) by the intermediate and most experienced readers,
respectively.
Intrareader agreement (i.e., within reader, between SUVr and
BPND) differed among readers, with moderate agreement (k 5
0.52) between methods seen in the reader with least experience,
excellent agreement (k 5 0.97) in the reader with moderate ex-
perience, and good agreement in the reader with most experience
(k 5 0.76).
When applying majority rules (i.e., 2 of 3 readers agreed on a
scan being either positive or negative), positivity was assigned to
27 (14%) cases based on SUVr and to 25 (13%) cases based on
BPND, with 22 overlapping cases. Thus, 8 cases showed inter-
method discordance; that is, 5 cases were rated positive on SUVr
but negative on BPND, and 3 cases were rated positive on BPND but
negative on SUVr. The remaining 160 cases were classified as
negative on both images (Fig. 2A).
Visual Reads Related to Quantitative Measures
For the total cohort, mean global SUVr and BPND were 1.33 6
0.21 and 0.16 6 0.12, respectively. There was good agreement
between both measures (intraclass correlation coefficient, 0.89;
P , 0.01). Interreader-concordant positive cases had signifi-
cantly higher SUVr and BPND than concordant negative cases
TABLE 1
Demographics, MRI Measurements, and PET Values
Parameter Data
Total cohort (n) 190
Women (n) 113 (59.5%)
Age (y) 70.4 ± 7.56
MMSE score 29 ± 1.13
Education (y) 15.15 ± 4.42
Global cortical atrophy score (0–3) 0.79 ± 0.72
Medial temporal atrophy score (0–4) 0.65 ± 0.72
Fazekas score (0–3)* 1.18 ± 0.82
Quantitative cohort (n) 185
SUVr
Mean ± SD 1.33 ± 0.21
Range 0.79–2.13
BPND
Mean ± SD 0.16 ± 0.12
Range 0.20–0.66
Concordant cohort (n) 149
PET-negative (n) 130
Global cortical atrophy score (0–3) 0.74 ± 0.67
Medial temporal atrophy score (0–4) 0.57 ± 0.64
Fazekas score (0–3)* 1.18 ± 0.83
SUVr
Mean ± SD 1.25 ± 0.09
Range 1.08–1.63
BPND
Mean ± SD 0.12 ± 0.05
Range 0.02–0.27
PET-positive (n) 19
Global cortical atrophy score (0–3) 0.89 ± 0.81
Medial temporal atrophy score (0–4) 0.82 ± 0.75
Fazekas score (0–3)* 1.26 ± 0.87
SUVr
Mean ± SD 1.83 ± 0.16§
Range 1.54–2.13
BPND
Mean ± SD 0.43 ± 0.12§
Range 0.27–0.66
*White matter hyperintensity (0 5 35; 1 5 101; 2 5 40; 3 5 14).
§P , 0.01, compared with PET-negative group.
FIGURE 1. Examples of SUVr and BPND 18F-flutemetamol images of 3
different patients. From left to right are shown axial, coronal, and sagittal
views. The 3 boxes on right represent amyloid classification by 3 readers
(red 5 negative; green 5 positive). Subject 1: Example of difficult case,
represented by discordant visual reads on both SUVr and BPND image.
Subject 2: Example of possible overestimation of amyloid pathology
when only SUVr image is assessed. Subject 3: Example of clearly pos-
itive case.
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(P , 0.01) (Table 1). Based on the visual read–concordant cohort
alone (n 5 149), the cutoff for positivity was 1.52 for SUVr (area
under the curve, 0.98; sensitivity, 95%; specificity, 98%) and 0.26
for BPND (area under the curve, 1.00; sensitivity, 100%; specificity,
98%) using a receiver-operating-characteristic analysis (Sup-
plemental Fig. 1; supplemental materials are available at http://
jnm.snmjournals.org). After applying both cutoffs to the data-
set, the agreement between the SUVr majority visual read and
semiquantitative negative–positive classification was good (k 5
0.78), with 16 cases (9%) discordant between the 2 classification
methods. The agreement analysis was also done with a literature-
based cutoff (1.56) (8,29) resulting in a k increase of 0.01. For
BPND, the agreement between the majority visual read and the
quantitative negative–positive classification was excellent (k 5
0.93), with 3 cases (2%) discordant between the 2 classification
methods. Most of the 35 cases (91%) for which SUVr image as-
sessment was discordant between readers were classified as negative
using either cutoff (Fig. 2B). In addition, in the 8 cases with a
discordant intermethod visual read, there was full agreement be-
tween visual and quantitative measurements when BPND was
used, which was not the case with SUVr (Fig. 2A).
SUVr ≠ BPND Quantification
We investigated the relationship between the 2 quantitative
measures with regard to the majority visual read to assess any
violations of the equilibrium assumptions (i.e., SUVr – 15 BPND)
in this population. For all cases except one, global SUVr – 1
values overestimated the corresponding global BPND values. Par-
ticipants with a positive read (mean overestimation [difference
SUVR 2 1 and BPND] 5 0.37 6 0.11) had a significantly higher
overestimation than participants with a negative read (mean over-
estimation 5 0.14 6 0.07; P , 0.01). This relationship was also
observed on a regional level, with the frontal lobe displaying the
highest mean binding and the largest mean SUVr overestimation,
compared with the parietal (P , 0.01) and temporal (P , 0.01)
lobes. In turn, the parietal lobe did not show a significantly higher
mean binding (P 5 0.1) but did show a significantly larger over-
estimation (P , 0.01) than the temporal lobe (Supplemental Fig. 2;
Table 1). The SUVr overestimation seems to have a limited influence
on the visual read of the high-binding group (i.e., BPND . 0.26),
considering no cases were visually assessed as positive on SUVr
and negative on BPND and only 2 SUVr images (7%) had a dis-
cordant read. For the low-binding group (i.e., BPND # 0.26), the
SUVr overestimation might have influenced the visual read, con-
sidering that 26 cases (16%) had a SUVr-discordant visual read.
However, no obvious pattern was discernible (Fig. 3).
DISCUSSION
In a cognitively normal elderly population with low amyloid
burden, we show a considerable improvement in interreader agree-
ment of 18F-flutemetamol visual assessment when using BPND
rather than standard SUVr images. Misclassifications can be re-
duced using semiquantitative SUVr measures and avoided using
fully quantitative BPND measures.
Our results are in line with the 11C-Pittsburgh compound B
findings of Zwan et al., who found a comparable improvement in
interreader agreement using BPND images (11). This result sug-
gests that the underlying reason for discrepant interreader agree-
ments was tracer-independent and likely related to the distinctive
metrics being used (SUVr and BPND). SUVr is commonly used
as a proxy for BPND, under the assumption that a secular equi-
librium is reached during scanning. However, these equilibrium
conditions are rarely met in practice. As such, whereas parametric
FIGURE 2. Scatterplot of quantitative measures compared with visual read. On x-axis is global cortical binding derived from BPND. On y-axis is
global cortical binding derived from SUVr. Reference lines denote cutoff (1.52 for SUVr and 0.26 for BPND). Different colors demonstrate discordance
or concordance between SUVr and BPND visual read. (A) Visual read based on majority rules. For all intermethod discordant cases (red circles and
orange squares), BPND visual read was in accordance with quantitative value, whereas SUVr was not. (B) Most SUVr interreader discordant cases
(red circles) are below cutoff for both SUVr and BPND.
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BPND images reflect the density of available receptors (amyloid
plaques), SUVr images are affected by a nondisplaceable (free
and nonspecific) signal and may be affected by changes in re-
gional flow and washout effects (28,30). As a result, SUVr can
overestimate specific binding (10) and influence visual assess-
ments (Fig. 3). Furthermore, our existing data show that this
overestimation is not constant but instead increases with higher
tracer binding (10,28).
The interreader agreement for the SUVr images and the concor-
dance between semiquantitative and corresponding visual read clas-
sifications in our study are lower than previously reported (7–9).
However, previous results were based on a clinical population of
end-of-life subjects with a higher incidence of moderate to se-
vere amyloid burden, which highlights the challenge of assess-
ing amyloid pathology in a population with low amyloid burden.
The challenge could be due to the nonspecific white matter
uptake seen with 18F-flutemetamol, which together with the
overestimation resulting from static scanning may translate into
a tendency to visually assign regions as positive (31). In our
study, the frontal regions were most often perceived as difficult
to assess, leading to the greatest doubt for final classification.
Although the 18F-flutemetamol reader training focuses on disen-
tangling the white matter pattern from the cortical signal, assess-
ment in this population seems additionally challenging, especially
for less experienced readers. Indeed, the positive-assigning ten-
dency was the strongest for the reader with the least experience,
who also showed the lowest intrareader agreement between meth-
ods. This result stresses the need for experienced readers to make
early assessments or for the reading guidelines to be updated, with
the focus being on a cognitively normal elderly population. Of
note, whereas the reference region used for visual assessment (i.e.,
pons) is different from that used for quantitative assessment (i.e.,
gray matter cerebellum), a separate agreement analysis using pons
for quantification did not affect the agreement between classifica-
tion methods.
Our results may have consequences for drug-intervention studies
focused on early populations, since using the visual assessment of
SUVr images as an inclusion criterion could result in false-positive
inclusion due to the observed overestimation of cortical amyloid
burden (32,33). Also, studies indicate that cerebral blood flow can
change with age and disease progression (34,35). Therefore, using
BPND images in clinical trials could avoid false-positive classifica-
tion in visual assessment (28) and ensure that measured changes are
due to the treatment instead of a measurement error or blood flow
confounders.
An important factor in considering dynamic PET acquisition is
participant burden. In this cohort, 95% of participants indicated
they had no objections to undergoing a second dynamic PET scan.
The coffee-break protocol used in this study may have facilitated
this response and suggests the feasibility of longitudinal dynamic
acquisition in cognitively normal elderly persons.
In a clinical setting, however, amyloid burden will more likely
be moderate to severe and dynamic acquisition more challeng-
ing. In addition, the utility of SUV or SUVr visual reads for the
diagnosis of AD-type dementia in a clinical setting has been
extensively shown (36). Thus, in this context, visual assessment
of SUVr images may indeed be sufficient. Nevertheless, the pre-
sent results illustrate that semiquantification using SUVr can
help reduce false-positive classification, especially in a chal-
lenging population. Thus, the clinical preference for visual as-
sessment could be revised in light of more available automatic
FIGURE 3. Illustration of binding overestimation for semiquantitative
PET acquisition. (A) From left to right are shown axial, coronal, and sag-
ittal views. SUVr images with subtraction of 1 show clearly higher binding
values than BPND images, whereas in theory these images should be
same. (B and C) Diagrams showing difference between SUVr − 1 and
BPND for each subject with regard to visual read. Overestimation of
SUVr is higher with increasing cortical binding.
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semiquantification methods, such as the one already provided for
18F-flutemetamol PET scans (8).
In this study, the standard manufacturer guidelines were used
for reading both SUVr and BPND images. Nonetheless, an inter-
esting finding was the improvement in interreader agreement for
BPND images despite the lack of official guidelines and the limited
experience of readers in assessing such images. However, it might
still be of interest to formally assess whether the current guide-
lines are optimal for assessing BPND images. In addition, opti-
mizing visual assessment of SUVr images by updating the
current guidelines and providing training specifically focused
on early accumulation may also improve the certainty of classi-
fication, comparable to that observed using dynamically derived
measures. Studies have suggested that, specifically, medial fron-
tal, anterior/posterior/isthmus cingulate cortex, and precuneus
are early-accumulating regions (37,38). These regions can be
visually assessed using the sagittal view of the PET image. Thus,
the importance of this plane may be of most interest for updating
guidelines.
A limitation of this study is the lack of a gold standard, as no
postmortem data were available, hampering the understanding of
the findings in relation to underlying neuropathology. Further-
more, although the frequency of amyloid positivity in this cohort
is comparable to previous reports (39), the low incidence may have
induced reader bias with regard to searching for amyloid positivity.
Lastly, both quantification and visual assessment of the PET images
in this study were accompanied by structural MRI, which might not
always be available.
CONCLUSION
The use of parametric BPND images for visual assessment of
18F-flutemetamol in a population with low amyloid burden im-
proves interreader agreement. Implementing semiquantification in
addition to visual assessment of SUVr images can reduce false-
positive classification in this population.
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